These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2481946)

  • 1. Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo.
    Hoffmann H; Siebeck M; Thetter O; Jochum M; Fritz H
    Adv Exp Med Biol; 1989; 247B():35-42. PubMed ID: 2481946
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the kinin-induced pathomechanisms in the development of ARDS by kallikrein inhibition in vivo.
    Thetter O; Hoffmann H; Siebeck M; Welter HF; Fritz H
    Prog Clin Biol Res; 1987; 236A():127-31. PubMed ID: 2441403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of covalent binding of aprotinin with a polysaccharide carrier on its inhibition of kallikrein from human plasma, porcine pancreatic kallikrein and trypsin].
    Larionova NI; Makevnina LG; Nartikova VF; Paskhina TS
    Biokhimiia; 1987 May; 52(5):825-31. PubMed ID: 2439135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinin and myocardial infarction: effect of Trasylol on the plasma prekallikrein and kallikrein inhibitor.
    Del Bianco PL; Franchi G; Lombardi M; Caleri D; Curradi C; Sicuteri F
    Adv Biosci; 1978 Jul; 17():187-95. PubMed ID: 314912
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock.
    Siebeck M; Fink E; Weipert J; Jochum M; Fritz H; Spannagl M; Kroworsch P; Shimamoto K; Schweiberer L
    J Trauma; 1993 Feb; 34(2):193-8. PubMed ID: 7681484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the plasma-kallikrein-kininogen system.
    Colman RW
    Adv Exp Med Biol; 1986; 198 Pt B():1-10. PubMed ID: 3643721
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of aprotinin and C1-esterase inhibitor on activation of the plasma kallikrein-kinin system in vivo.
    Hoffmann H; Siebeck M; Thetter O; Fink E; Philapitsch A
    Prog Clin Biol Res; 1987; 236A():159-64. PubMed ID: 2441405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Status of the kallikrein-kinin system in abortion].
    Kheĭfets SN; Zolotukhina NS
    Akush Ginekol (Mosk); 1987 Oct; (10):18-9. PubMed ID: 2449091
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass.
    Fuhrer G; Gallimore MJ; Heller W; Hoffmeister HE
    Adv Exp Med Biol; 1986; 198 Pt B():385-91. PubMed ID: 2433915
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: role of Factor XI.
    Nielsen VG
    Acta Anaesthesiol Scand; 2006 Feb; 50(2):168-72. PubMed ID: 16430537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kallikrein activation and kininogen level in rat venous and arterial blood in acute myocardial ischemia].
    Gomazkov OA; Komissarova NV; Bol'shakova LV; Shimkovich MV
    Biull Eksp Biol Med; 1973 Aug; 76(8):25-7. PubMed ID: 4544262
    [No Abstract]   [Full Text] [Related]  

  • 12. Semisynthetic arginine-15-aprotinin, an improved inhibitor for human plasma kallikrein.
    Tschesche H; Beckmann J; Mehlich A; Feldmann A; Wenzel HR; Scott CF; Colman RW
    Adv Exp Med Biol; 1989; 247B():15-21. PubMed ID: 2481943
    [No Abstract]   [Full Text] [Related]  

  • 13. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital deficiency in plasma kallikrein and kininogens in the brown Norway rat.
    Damas J; Adam A
    Experientia; 1980 May; 36(5):586-7. PubMed ID: 6900563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo inhibition of tissue kallikreins by kininogen sequence analogue peptides.
    Okunishi H; Spragg J; Burton J; Toda N
    Adv Exp Med Biol; 1989; 247B():23-8. PubMed ID: 2481944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the kallikrein-kinin system in Rocky Mountain spotted fever.
    Yamada T; Harber P; Pettit GW; Wing DA; Oster CN
    Ann Intern Med; 1978 Jun; 88(6):764-8. PubMed ID: 307354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of commercial polyvalent proteinase inhibitors. Comparative analysis of their effect on kallikreins from different sources and trypsin].
    Iarovaia GA; Dotsenko VL; Agapova EI; Stepanian EP
    Vopr Med Khim; 1980; 26(6):832-7. PubMed ID: 6161484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatic protein synthesis of the kallikrein-kininogen-kinin system].
    Adam A; Reynaert M; Damas P; Ers P; Boulanger J; Roeseler J; Faymonville ME; Lamy M; Damas J
    Presse Med; 1988 Feb; 17(4):151-4. PubMed ID: 2964610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [State of the kallikrein-kinin system and anti-enzyme therapy in acute peritonitis in children].
    Matskevich BI
    Vestn Khir Im I I Grek; 1982 Aug; 129(8):90-4. PubMed ID: 6182678
    [No Abstract]   [Full Text] [Related]  

  • 20. Kallikrein inhibitor (aprotinin): plasma turnover and effects on coagulation in rhesus monkeys.
    De Sa Pereira M
    Adv Exp Med Biol; 1979; 120B():341-7. PubMed ID: 117681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.